MedTrace Logo

Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders

NCT00538811 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-10-27

No results posted yet for this study

Summary

When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.

Conditions

  • Hepatitis C
  • Genotype 3
  • Non-responders
  • Relapsers

Interventions

DRUG

interferon alpha-2b, ribavirin, interferon-gamma,

DRUG

interferon alpha-2b, ribavirin, amantadine

Sponsors & Collaborators

  • Aga Khan University

    lead OTHER

Principal Investigators

  • Zaigham Abbas, FCPS, FACG · The Aga Khan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00538811 on ClinicalTrials.gov